Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01497444
Title Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors North Central Cancer Treatment Group
Indications

liver cancer

kidney cancer

Therapies

Evofosfamide + Sorafenib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.